148465-45-6

Basic information

• Product Name: SP 303
• Synonyms: SP 303;Crofelemer;Provir;Virend
• CAS NO: 148465-45-6
• Molecular Weight: 308.33124
• Mol File: 148465-45-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: SP 303(CAS DataBase Reference)
• NIST Chemistry Reference: SP 303(148465-45-6)
• EPA Substance Registry System: SP 303(148465-45-6)

Safety Data

• Hazardous Substances Data: 148465-45-6(Hazardous Substances Data)

Usage

Description

Crofelemer was approved by the US FDA in December 2012 for the treatment of diarrhea in HIV/AIDS patients on antiretroviral therapy. Crofelemer is indicated for a subset of the population (30–40% of HIV/AIDS cases) whose diarrhea is determined to be noninfective in origin. Crofelemer is an oligomeric proanthocyanidin natural product that is isolated fromthe red latex of Croton lechleri and has been historically used by traditional practitioners of medicine in South America to treat diarrhea. Previously known as SP-303, crofelemer has been shown to inhibit chloride secretion across epithelial cell monolayers, which causes concomitantmovement of water and sodium.

Originator

Shaman Pharmaceuticals (South America (natural product)/United States (Shaman Pharmaceuticals))

Uses

Antidiarrheal; antiviral.

Brand name

Provir (Shaman); Virend (Shaman);Fulyzaq.

Upstream product

• 9012-76-4 chitosan 

Downstream Products

• 709-19-3 2-methyl-1H-benzoimidazole-5-carboxylic acid 
• 65133-69-9 2-(2-hydroxyethoxy)ethyl 2-hydroxyethyl terephthalate 
• 959-26-2 Bis(2-Hydroxyethyl)terephthalat 
• 111-46-6 diethylene glycol 

Relevant articles and documents

Hydrogel Nanocompsites for Ophthalmic Applications

The present invention relates to reversible hydrogel systems. Particularly, the hydrogel of the present invention is made up of copolymers that can be a hydrogel when in an oxidized state and can be a solution when in a reduced state. A solution of the copolymer can be oxidized to form a hydrogel; and the hydrogel can be reduced to form a solution of the copolymer. Reversible nanogels can also be formed from a dilute solution of the copolymers. The hydrogel is formed with nanoparticles embedded therein to form a nanocomposite whose refractive index and modulus can be controlled by varying the amounts of nanoparticles and the polymer concentration of the hydrogel, respectively

N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS

Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.